Immunovaccine to Present Data on Cancer Vaccine Combination Therapies at the 2014 AACR Annual Meeting
03 Aprile 2014 - 2:05PM
Marketwired
Immunovaccine to Present Data on Cancer Vaccine Combination
Therapies at the 2014 AACR Annual Meeting
Combining with cyclophosphamide and the checkpoint inhibitor
anti-PD-1 enhances the therapeutic potential of vaccine
HALIFAX, NOVA SCOTIA--(Marketwired - Apr 3, 2014) -
Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX-VENTURE:IMV), a
clinical stage vaccine company, today announced that data from
clinical and preclinical vaccine studies, including DPX-Survivac,
the company's lead therapeutic cancer vaccine, will be presented at
the American Association for Cancer Research (AACR) 2014 Annual
Meeting. The AACR Annual Meeting will be held April 5 - 9, 2014 in
San Diego, California.
The first poster presentation will focus on study findings that
support the belief that cancer treatment regimens that combine a
vaccine with immune modulating agents such as metronomic
cyclophosphamide, anti-PD-1 and anti-CTLA-4 may deliver enhanced
therapeutic benefits. Details of the poster presentation are as
follows:
Abstract #5028: |
Metronomic cyclophosphamide enhances the immunogenicity and
anti-tumor activity of a DepoVax based vaccine and may be further
enhanced with inhibitors of CTLA-4 or PD-1 |
|
|
|
Genevieve Weir, Research Scientist at Immunovaccine |
|
Poster Board #20 |
|
Sunday, April 6, 2014, 1:00 - 5:00 p.m. |
|
Location: Hall A-E Poster Section 27 |
A second poster related to DPX-Survivac in combination with
metronomic low dose cyclophosphamide will also be presented during
the AACR conference by Immunovaccine collaborator, Caprion's
ImmuneCarta business unit. This presentation will detail immune
response results from Immunovaccine's Phase I study of DPX-Survivac
in ovarian cancer patients. Details of the poster presentation are
as follows:
Abstract #CT411: |
Immune profiling of patients vaccinated with the survivin targeted
therapeutic vaccine DPX-Survivac demonstrates durable
polyfunctional CD4+ and CD8+ T cells in ovarian cancer
patients |
|
|
|
Yoav
Peretz, Ph.D., Principal Scientist at ImmuneCarta Services |
|
Poster Board #11 |
|
Wednesday, April 9, 2014, 8:00 a.m. - 12:00 p.m. |
|
Location: Hall A-E Poster Section 38 |
About DPX-Survivac
DPX-Survivac consists of survivin-based peptide antigens
formulated in the DepoVax™ adjuvanting platform. Survivin has been
recognized by the National Cancer Institute (NCI) as a promising
tumor-associated antigen (TAA) because of its therapeutic potential
and its cancer specificity. Survivin is broadly over-expressed in
solid tumors and blood cancers including ovarian, breast, colon and
lung cancers, among others. Survivin plays an essential role in
antagonizing apoptosis, supporting tumor-associated angiogenesis,
and promoting resistance to various anti-cancer therapies. Survivin
is also a prognostic factor for many cancers and it is found in a
high percentage of cancer patients.
The DPX-Survivac vaccine is thought to work by eliciting a
cytotoxic T-cell immune response against cells presenting survivin
peptides on HLA class I molecules. This targeted therapy attempts
to use the immune system to actively search for tumor cells
expressing survivin and destroy them.
About Immunovaccine
Immunovaccine Inc. develops cancer immunotherapies and
infectious disease vaccines based on the Company's DepoVax™
platform, a patented formulation that provides controlled and
prolonged exposure of antigens and adjuvants to the immune system.
Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine
therapy, DPX-Survivac, is expected to enter Phase II clinical
studies in 2014, in ovarian cancer and glioblastoma (brain cancer).
The Company is also advancing an infectious disease pipeline
including innovative vaccines for respiratory syncytial virus (RSV)
and anthrax.
Connect at www.imvaccine.com.
This press release contains forward-looking information
under applicable securities law. All information that addresses
activities or developments that we expect to occur in the future,
is forward-looking information. Forward-looking statements are
based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Immunovaccine Inc.Dr. Marc MansourChief Operating Officer(902)
492-1819mmansour@imvaccine.comwww.imvaccine.comVida Strategic
Partners (media)Tim Brons(415) 675-7402tbrons@vidasp.com
Grafico Azioni (TSXV:IMV)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni (TSXV:IMV)
Storico
Da Ott 2023 a Ott 2024